Marek's disease: Genetic regulation of gallid herpesvirus 2 infection and latency

Veterinary Journal

Volumn 205, Issue 3, 2015, Pages 339-348

  Gennart, Isabelle ^a   Coupeau, Damien ^a   Pejaković, Srdan ^a   Laurent, Sylvie ^b   Rasschaert, Denis ^b   Muylkens, Benoit ^a  

^a University of Namur   (Belgium)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Epigenetics; Gallid herpesvirus 2; Gene regulation; Marek's disease; Virus induced lymphoma

Indexed keywords

ARGININE DIPEPTIDE; DIPEPTIDE; INTERLEUKIN 8; MICRORNA; MICRORNA 21; MICRORNA M11; MICRORNA M11 M1; MICRORNA M12; MICRORNA M2; MICRORNA M2 5P; MICRORNA M3; MICRORNA M3 5P; MICRORNA M31; MICRORNA M4; MICRORNA M4 3P; MICRORNA M4 5P; MICRORNA M5; MICRORNA M7 5P; MICRORNA M8 M10; MICRORNA M9; MICRORNA M9 5P; MICRORNA M9 M4; MYC PROTEIN; ONCOPROTEIN MEQ; PROTEIN P53; SERINE DIPEPTIDE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA; VIRUS PROTEIN;

DNA METHYLATION; DNA MODIFICATION; GENE EXPRESSION; GENETIC REGULATION; HISTONE MODIFICATION; MAREK DISEASE; MAREK'S DISEASE VIRUS 1; NONHUMAN; PROMOTER REGION; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION REGULATION; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; BIRD DISEASE; CHICKEN; GENE EXPRESSION REGULATION; GENETICS; HUMAN; VIROLOGY; VIRUS LATENCY;

GALLID HERPESVIRUS 2; GALLUS GALLUS; HERPESVIRIDAE;

ANIMALS; CHICKENS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 2, GALLID; HUMANS; MAREK DISEASE; POULTRY DISEASES; VIRUS LATENCY;

EID: 84938743522     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2015.04.038     Document Type: Review

References (77)

1. Ajithdoss D.K., Reddy S.M., Suchodolski P.F., Lee L.F., Kung H.J., Lupiani B. In vitro characterization of the Meq proteins of Marek's disease virus vaccine strain CVI988. Virus Research 2009, 142:57-67.
2. Amor S., Strassheim S., Dambrine G., Remy S., Rasschaert D., Laurent S. ICP27 protein of Marek's disease virus interacts with SR proteins and inhibits the splicing of cellular telomerase chTERT and viral vIL8 transcripts. Journal of General Virology 2011, 92:1273-1278.
3. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
4. Baigent S.J., Davison F. Marek's disease virus: Biology and life cycle. Biology of Animal Infections. Marek's Disease: An Evolving Problem 2004, 62-77. Elsevier Academic Press, Amsterdam, The Netherlands. F. Davison, V. Nair (Eds.).
5. Barrow A.D., Burgess S.C., Baigent S.J., Howes K., Nair V.K. Infection of macrophages by a lymphotrophic herpesvirus: A new tropism for Marek's disease virus. Journal of General Virology 2003, 84:2635-2645.
6. Biggs P.M., Nair V. The long view: 40 years of Marek's disease research and avian pathology. Avian Pathology 2012, 41:3-9.
7. Brown A.C., Baigent S.J., Smith L.P., Chattoo J.P., Petherbridge L.J., Hawes P., Allday M.J., Nair V. Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus. Proceedings of the National Academy of Sciences of the United States of America 2005, 103:1687-1692.
8. Brown A.C., Nair V., Allday M.J. Epigenetic regulation of the latency-associated region of Marek's disease virus in tumor-derived T-cell lines and primary lymphoma. Journal of Virology 2012, 86:1683-1695.
9. Bulow V.V., Biggs P.M. Differentiation between strains of Marek's disease virus and turkey herpesvirus by immunofluorescence assays. Avian Pathology 1975, 4:133-146.
10. Bulow V.V., Biggs P.M. Precipitating antigens associated with Marek's disease viruses and a herpesvirus of turkeys. Avian Pathology 1975, 4:147-162.
11. Burgess S.C., Young J.R., Baaten B.J.G., Hunt L., Ross L.N.J., Parcells M.S., Kumar P.M., Tregaskes C., Lee L.F., Davison T.F. Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30). Proceedings of the National Academy of Sciences of the United States of America 2004, 101:13879-13884.
12. Burnside J., Bernberg E., Anderson A., Lu C., Meyers B.C., Green P.J., Jain N., Isaacs G., Morgan R.W. Marek's disease virus encodes MicroRNAs that map to meq and the latency-associated transcript. Journal of Virology 2006, 80:8778-8786.
13. Burnside J., Ouyang M., Anderson A., Bernberg E., Lu C., Meyers B.C., Green P.J., Markis M., Isaacs G., Huang E., et al. Deep sequencing of chicken microRNAs. BMC Genomics 2008, 9:185.
14. Calnek B.W., Schat A., Peckham C., Fabricant J. Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease. Avian Diseases 1982, 27:844-849.
15. Cauchy L., Coudert F. La maladie de Marek. Revue Scientifique et Technique (Office International des Épizooties) 1986, 5:1011-1024.
16. Chbab N., Egerer A., Veiga I., Jarosinski K.W., Osterrieder N. Viral control of vTR expression is critical for efficient formation and dissemination of lymphoma induced by Marek's disease virus (MDV). Veterinary Research 2010, 41:56.
17. Chen R., Ding J., Wang B. The construction and characterization of the bi-directional promoter between pp38 gene and 1.8-kb mRNA transcripts of Marek's disease viruses. Virology Journal 2009, 6:1-6.
18. Churchill A.E. Herpes-type virus isolated in cell culture from tumors of chickens with Marek's disease. I. Studies in cell culture. Journal of the National Cancer Institute 1968, 41:939-950.
19. Churchill A.E., Biggs P.M. Agent of Marek's disease in tissue culture. Nature 1967, 215:528-530.
20. Churchill A.E., Chubb R.C. The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture. Journal of General Virology 1969, 4:557-564.
21. Coupeau D., Dambrine G., Rasschaert D. Kinetic expression analysis of the cluster mdv1-mir-M9-M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. Journal of General Virology 2012, 93:1519-1529.
22. Davison F., Nair V. Marek's disease: An evolving problem 2004, Proceedings of the 7th International Marek's Disease Symposium. Oxford, UK, 10-14 July 2004. Institute for Animal Health, Compton, UK/Office International des Epizooties, Paris, France, pp. 62-76.
23. + T cells. Journal of Virology 2012, 86:8536-8545.
24. Fragnet L., Blasco M.A., Klapper W., Rasschaert D. The RNA subunit of telomerase is encoded by Marek's disease virus. Journal of Virology 2003, 77:5985-5996.
25. Fragnet L., Kut E., Rasschaert D. Comparative functional study of the viral telomerase RNA based on natural mutations. Journal of Biological Chemistry 2005, 280:23502-23515.
26. Gimeno I.M. Marek's disease vaccines: A solution for today but a worry for tomorrow?. Vaccine 2008, 26:C31-C41.
27. Gimeno I.M., Witter R.L., Hunt H.D., Reddy S.M., Lee L.F., Silva R.F. The pp38 gene of Marek's disease virus (MDV) is necessary for cytolytic infection of B cells and maintenance of the transformed state but not for cytolytic infection of the feather follicle epithelium and horizontal spread of MDV. Journal of Virology 2005, 79:4545-4549.
28. Günther T., Grundhoff A. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathogens 2010, 6. e1000935.
29. Hardwicket M.A.N.N., Sandri-Goldin R.M. The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection. Journal of Virology 1994, 68:4797-4810.
30. Hardy W.R., Sandri-Goldin R.M. Herpes simplex virus inhibits host cell splicing, and regulatory protein ICP27 is required for this effect. Journal of Virology 1994, 68:7790.
31. Hayashi M., Kawamura T., Akaike H., Arai S., Okui T. Antisense oligonucleotide complementary to the BamHI-H gene family of Marek's disease virus induced growth arrest of MDCC-MSB1 cells in the S-phase. Journal of Veterinary Medical Science 1999, 61:389-394.
32. Isfort R.J., Stringer R.A., Kung H., Velicer L.F. Synthesis, processing, and secretion of the Marek's disease herpesvirus A antigen glycoprotein. Journal of Virology 1986, 57:464.
33. Jarosinski K.W., Schat K.A. Multiple alternative splicing to exons II and III of viral interleukin-8 (vIL-8) in the Marek's disease virus genome: The importance of vIL-8 exon I. Virus Genes 2007, 34:9-22.
34. Jiabo D., Zhizhong C.U.I., Shijin J., Yanpeng L.I. Study on the structure of heteropolymer pp38/pp24 and its enhancement on the bi-directional promoter upstream of pp38 gene in Marek's disease virus. Life Sciences 2008, 51:821-826.
35. Kanamori A., Ikuta K., Ueda S., Kato S., Hirai K. Methylation of Marek's disease virus DNA in chicken T-lymphoblastoid cell lines. Journal of General Virology 1987, 68:1485-1490.
36. Kaufer B.B., Trapp S., Jarosinski K.W., Osterrieder N. Herpesvirus telomerase RNA (vTR)-dependent lymphoma formation does not require interaction of vTR with telomerase reverse transcriptase (TERT). PLoS Pathogens 2010, 6. e1001073.
37. Kaufer B.B., Jarosinski K.W., Osterrieder N. Herpesvirus telomeric repeats facilitate genomic integration into host telomeres and mobilization of viral DNA during reactivation. Journal of Experimental Medicine 2011, 208:605-615.
38. Lambeth L.S., Yao Y., Smith L.P., Zhao Y., Nair V. MicroRNAs 221 and 222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1. Journal of General Virology 2009, 90:1164-1171.
39. Laurent S., Blondeau C., Belghazi M., Remy S., Esnault E., Rasschaert P., Rasschaert D. Sequential autoprocessing of Marek's disease herpesvirus protease differs from that of other herpesviruses. Journal of Virology 2007, 81:6117-6121.
40. Lee L.F., Lupiani B., Silva R.F., Kung H.-J., Reddy S.M. Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV. Vaccine 2008, 26:1887-1892.
41. Lee L.F., Heidari M., Zhang H., Lupiani B., Reddy S.M., Fadly A. Cell culture attenuation eliminates rMd5δMeq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease. Vaccine 2012, 30:5151-5158.
42. Levy A.M., Izumiya Y., Brunovskis P., Xia L., Parcells M.S., Reddy S.M., Lee L., Chen H., Kung H., Irol J.V. Characterization of the chromosomal binding sites and dimerization partners of the viral oncoprotein Meq in Marek's disease. Journal of Virology 2003, 77:12841-12851.
43. Levy A.M., Gilad O., Xia L., Izumiya Y., Choi J., Tsalenko A., Yakhini Z., Witter R., Lee L., Cardona C.J., et al. Marek's disease virus Meq transforms chicken cells via the v-Jun transcriptional cascade: A converging transforming pathway for avian oncoviruses. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:14831-14836.
44. Liang Y., Vogel J.L., Narayanan A., Peng H., Kristie T.M. Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. Nature Medicine 2009, 15:1312-1317.
45. Liu J., Kung H. Marek's disease herpesvirus transforming protein MEQ: A c-Jun analogue with an alternative life style. Virus Genes 2000, 21:51-64.
46. Majerciak V., Yamanegi K., Allemand E., Kruhlak M., Krainer A.R., Zheng Z.M. Kaposi's sarcoma-associated herpesvirus ORF57 functions as a viral splicing factor and promotes expression of intron-containing viral lytic genes in spliceosome-mediated RNA splicing. Journal of Virology 2008, 82:2792-2801.
47. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
48. Murata T., Tsurumi T. Epigenetic modification of the Epstein-Barr virus BZLF1 promoter regulates viral reactivation from latency. Frontiers in Genetics 2013, 4:53.
49. Murata T., Tsurumi T. Switching of EBV cycles between latent and lytic states. Reviews in Medical Virology 2014, 24:142-153.
50. Muylkens B., Coupeau D., Dambrine G., Trapp S., Rasschaert D. Marek's disease virus microRNA designated Mdv1-pre-miR-M4 targets both cellular and viral genes. Archives of Virology 2010, 155:1823-1837.
51. Nicoll M.P., Proença J.T., Efstathiou S. The molecular basis of herpes simplex virus latency. Federation of European Microbiological Societies 2012, 36:684-705.
52. Nojima T., Oshiro-Ideue T., Nakanoya H., Kawamura H., Morimoto T., Kawaguchi Y., Kataoka N., Hagiwara M. Herpesvirus protein ICP27 switches PML isoform by altering mRNA splicing. Nucleic Acids Research 2009, 37:6515-6527.
53. Parnas O., Corcoran D.L., Cullen R. Analysis of the mRNA targetome of microRNAs expressed by Marek's disease virus. MBio 2014, 5. e01060-13.
54. Qian Z., Brunovskis P., Iii F.R., Lee L., Kung H. Transactivation activity of Meq, a Marek's disease herpesvirus bZIP protein persistently expressed in latently infected transformed T cells. Journal of Virology 1995, 69:4037-4044.
55. Qian Z., Brunovskis P., Lee L., Vogt P.K., Kung H.J. Novel DNA binding specificities of a putative herpesvirus bZIP oncoprotein. Journal of Virology 1996, 70:7161-7170.
56. Robinson C.M., Hunt H.D., Cheng H.H., Delany M.E. Chromosomal integration of an avian oncogenic herpesvirus reveals telomeric preferences and evidence for lymphoma clonality. Herpesviridae 2010, 1:5.
57. Ruvolo V., Sun L., Howard K., Sung S., Delecluse H., Hammerschmidt W., Swaminathan S. Functional analysis of Epstein-Barr virus SM protein: Identification of amino acids essential for structure, transactivation, splicing inhibition, and virion production. Journal of Virology 2004, 78:340-352.
58. Schumacher D., Tischer B.K., Fuchs W., Osterrieder N. Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant. Journal of Virology 2000, 74:11088-11098.
59. Sedlackova L., Perkins K.D., Lengyel J., Strain A.K., van Santen V.L., Rice S. Herpes simplex virus type 1 ICP27 regulates expression of a variant, secreted form of glycoprotein C by an intron retention mechanism. Journal of Virology 2008, 82:7443-7455.
60. Shek W.R., Calnek B.W., Schat K.A., Chen C.H. Characterization of Marek's disease virus-infected lymphocytes: Discrimination between cytolytically and latently infected cells. Journal of Virology 1983, 83:9131-9139.
61. Shigekane H., Kawaguchi Y., Shirakata M., Sakaguchi M., Hirai K. The bi-directional transcriptional promoters for the latency-relating transcripts of the pp38/pp24 mRNAs and the 1.8 kb-mRNA in the long inverted repeats of Marek's disease virus serotype 1 DNA are regulated by common promoter-specific enhancers. Archives of Virology 1999, 144:1893-1907.
62. Shkreli M., Dambrine G., Soubieux D., Kut E., Rasschaert D. Involvement of the oncoprotein c-Myc in viral telomerase RNA gene regulation during Marek's disease virus-induced lymphomagenesis. Journal of Virology 2007, 81:4848-4857.
63. Sithole I., Lee L.F., Velicer L.F. Synthesis and processing of the Marek's disease herpesvirus B antigen glycoprotein complex. Journal of Virology 1988, 62:4270.
64. Spatz S.J., Silva R.F. Sequence determination of variable regions within the genomes of gallid herpesvirus-2 pathotypes. Archives of Virology 2007, 152:1665-1678.
65. Stik G., Laurent S., Coupeau D., Coutaud B., Dambrine G., Rasschaert D., Muylkens B. A p53-dependent promoter associated with polymorphic tandem repeats controls the expression of a viral transcript encoding clustered microRNAs. RNA (New York, N.Y.) 2010, 16:2263-2276.
66. Stik G., Dambrine G., Pfeffer S., Rasschaert D. The oncogenic microRNA OncomiR-21 overexpressed during Marek's disease lymphomagenesis is transactivated by the viral oncoprotein Meq. Journal of Virology 2013, 87:80-93.
67. Stik G., Muylkens B., Coupeau D., Laurent S., Dambrine G., Messmer M., Chane-Woon-Ming B., Pfeffer S., Rasschaert D. Small RNA cloning and sequencing strategy affects host and viral microRNA expression signatures. Journal of Biotechnology 2014, 181:35-44.
68. Strassheim S., Stik G., Rasschaert D., Laurent S. mdv1-miR-M7-5p, located in the newly identified first intron of the latency-associated transcript of Marek's disease virus, targets the immediate-early genes ICP4 and ICP27. Journal of General Virology 2012, 93:1731-1742.
69. Tang S., Guo N., Patel A., Krause P.R. Herpes simplex virus 2 expresses a novel form of ICP34.5, a major viral neurovirulence factor, through regulated alternative splicing. Journal of Virology 2013, 87:5820-5830.
70. Tian F., Luo J., Zhang H., Chang S., Song J. MiRNA expression signatures induced by Marek's disease virus infection in chickens. Genomics 2012, 99:152-159.
71. Witter R.L. Increased virulence of Marek's disease virus field isolates. Avian Diseases 1997, 41:149-163.
72. Witter R.L., Lee L.F. Polyvalent Marek's disease vaccines: Safety, efficacy and protective synergism in chickens with maternal antibodies. Avian Pathology 1984, 13:75-92.
73. Xu S., Xue C., Li J., Bi Y., Cao Y. Marek's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of the transforming growth factor beta signal pathway. Journal of Virology 2011, 85:276-285.
74. Yao Y., Nair V. Role of virus-encoded microRNAs in avian viral diseases. Viruses 2014, 6:1379-1394.
75. Yao Y., Zhao Y., Smith L.P., Lawrie C.H., Saunders N.J., Watson M., Nair V. Differential expression of microRNAs in Marek's disease virus-transformed T-lymphoma cell lines. Journal of General Virology 2009, 90:1551-1559.
76. Yoshida S., Lee L.F., Yanagida N., Nazerian K. Mutational analysis of the proteolytic cleavage site of glycoprotein B (gB) of Marek's disease virus. Gene 1994, 150:303-306.
77. Zhao Y., Yao Y., Xu H., Lambeth L., Smith L.P., Kgosana L., Wang X., Nair V. A functional MicroRNA-155 ortholog encoded by the oncogenic Marek's disease virus. Journal of Virology 2009, 83:489-492.